New perspectives on migraine treatment: a review of the mechanisms and effects of complementary and alternative therapies
- PMID: 38784897
- PMCID: PMC11111892
- DOI: 10.3389/fneur.2024.1372509
New perspectives on migraine treatment: a review of the mechanisms and effects of complementary and alternative therapies
Abstract
Migraine is a prevalent and disabling neurovascular disorder, with women being more susceptible, characterized by unilateral throbbing headache, often accompanied by nausea and vomiting, and often associated with various comorbidities such as brain and cardiovascular diseases, which can have a serious impact on quality of life. Although nonsteroidal anti-inflammatory drugs (NSAIDs) are the main first-line medications for the treatment of pain, long-term use often leads to side effects and drug addiction, which emphasizes the need to investigate alternative pain management strategies with fewer adverse effects. Complementary and alternative medicine is a viable pain intervention often used in conjunction with traditional medications, including acupuncture, herbs, moxibustion, transcutaneous electrical stimulation, bio-supplements, and acupressure, which offer non-pharmacological alternatives that are now viable pain management options. This review focuses on the mechanistic doctrine of migraine generation and the role and potential mechanisms of Complementary and Alternative Therapies (CAT) in the treatment of migraine, summarizes the research evidences for CAT as an adjunct or alternative to conventional therapies for migraine, and focuses on the potential of novel migraine therapies (calcitonin gene-related peptide (CGRP) antagonists and pituitary adenylyl cyclase-activating peptide (PACAP) antagonists) with the aim of evaluating CAT therapies as adjunctive or alternative therapies to conventional migraine treatment, thereby providing a broader perspective on migraine management and the design of treatment programs for more effective pain management.
Keywords: acupuncture; alternative therapy; complementary therapy; migraine; pain management.
Copyright © 2024 Song, Zhu, Su, Shi, Chi, Yan, Luo, Xu, Liu, Liu and Yang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment.Cells. 2023 Nov 17;12(22):2649. doi: 10.3390/cells12222649. Cells. 2023. PMID: 37998384 Free PMC article. Review.
-
Future targets for migraine treatment beyond CGRP.J Headache Pain. 2023 Jun 28;24(1):76. doi: 10.1186/s10194-023-01567-4. J Headache Pain. 2023. PMID: 37370051 Free PMC article. Review.
-
New Trends in Migraine Pharmacology: Targeting Calcitonin Gene-Related Peptide (CGRP) With Monoclonal Antibodies.Front Pharmacol. 2019 Apr 9;10:363. doi: 10.3389/fphar.2019.00363. eCollection 2019. Front Pharmacol. 2019. PMID: 31024319 Free PMC article. Review.
-
Role of CGRP in Migraine.Handb Exp Pharmacol. 2019;255:121-130. doi: 10.1007/164_2018_201. Handb Exp Pharmacol. 2019. PMID: 30725283
-
Calcitonin Gene-Related Peptide (CGRP) and Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Migraine Pathogenesis.Pharmaceuticals (Basel). 2022 Sep 27;15(10):1189. doi: 10.3390/ph15101189. Pharmaceuticals (Basel). 2022. PMID: 36297301 Free PMC article. Review.
Cited by
-
Anti-Inflammatory Peptides as Promising Therapeutics Agent Against Inflammatory Bowel Diseases: A Systematic Review.JGH Open. 2025 Jun 29;9(7):e70212. doi: 10.1002/jgh3.70212. eCollection 2025 Jul. JGH Open. 2025. PMID: 40589771 Free PMC article. Review.
-
Melatonin as an anti-inflammatory hormone bridging migraine relief and cancer immunity enhancement: a literature review.Front Immunol. 2025 Jul 28;16:1644066. doi: 10.3389/fimmu.2025.1644066. eCollection 2025. Front Immunol. 2025. PMID: 40791587 Free PMC article. Review.
-
Mind over migraine: Disease burden, innovative therapies, and managed care trends in treating migraine disease.J Manag Care Spec Pharm. 2025 Jul;31(7-a Suppl):S1-S13. doi: 10.18553/jmcp.2025.31.7-a.s1. J Manag Care Spec Pharm. 2025. PMID: 40577027 Free PMC article.
-
New insights into the increased risk of migraines from COVID-19 infection and vaccination: a Mendelian randomization study.Front Neurol. 2024 Oct 25;15:1445649. doi: 10.3389/fneur.2024.1445649. eCollection 2024. Front Neurol. 2024. PMID: 39524914 Free PMC article.
-
Efficacy of foot reflexology in reducing migraine pain: a randomized controlled trial.Ann Med Surg (Lond). 2025 Apr 10;87(6):3221-3228. doi: 10.1097/MS9.0000000000003247. eCollection 2025 Jun. Ann Med Surg (Lond). 2025. PMID: 40486630 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous